Clinical application of target temperature management in children with acute encephalopathy—A practical review

Jainn-Jim Lin a,b,c,e, Shao-Hsuan Hsia a,e, Ming-Chou Chiang b,d,e, Kuang-Lin Lin c,e,*

a Division of Pediatric Critical Care and Pediatric Neurocritical Care Center, Chang Gung Children’s Hospital at Linkou, Taoyuan, Taiwan
b Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan
c Division of Pediatric Neurology, Chang Gung Children’s Hospital at Linkou, Taoyuan, Taiwan
d Division of Neonatology, Chang Gung Children’s Hospital at Linkou, Taoyuan, Taiwan
e College of Medicine, Chang Gung University, Taoyuan, Taiwan

Abstract
Acute encephalopathy is a life-threatening disease involving acute brain dysfunction, and it is one of the most important causes of mortality and severe neurological sequelae in infants and children. Approximately 30% of cases of acute encephalopathy result in some degree of neurological sequelae. Although many strategies have been proposed, effective therapies to ameliorate the outcomes of acute encephalopathy have not yet been established. Target temperature management (TTM), previously termed therapeutic hypothermia, has been shown to be effective for various brain injuries due to multiple neuroprotective mechanisms, and it may be considered to be the cornerstone of neuroprotective strategies. Consequently, TTM is currently used in the neurocritical care of adult patients with cardiac arrest with shockable rhythm and perinatal asphyxia. In addition, increasing evidence also indicates that TTM could be useful in other acute encephalopathies, including status epilepticus, acute encephalitis/encephalopathy and traumatic brain injury. In this review, we discuss the recent practical aspects of TTM as a potential intervention for various acute encephalopathies in children.
Fever (>38 °C) has been shown to exacerbate brain injury. Target temperature management (TTM), previously termed therapeutic hypothermia, has been shown to be effective for various brain injuries due to multiple neuroprotective mechanisms. These mechanisms include decreasing the metabolic rate to restore the supply and demand of oxygen, decreasing excitatory neurotransmitters (such as glutamate), limiting neuroinflammation, preventing ATP depletion, reducing free radical production and also intracellular calcium overload to avoid neuronal apoptosis. Consequently, TTM is currently used in neurocritical care of adult patients with cardiac arrest with an initial shockable rhythm and perinatal asphyxia [3–5]. Some case reports and series have also shown that TTM can be useful in other acute encephalopathies, including status epilepticus, acute encephalitis/encephalopathy, post-anoxic encephalopathy and hepatic encephalopathy. However, the protocols may differ with regards to the depth (target temperature) and duration of temperature management according to the clinical indications [6,7]. In this review, we summarize the recent practical aspects of TTM as a potential intervention for various acute encephalopathies in children.

**Pediatric cardiac arrest**

The etiology of pediatric cardiac arrest is different from adult cardiac arrest, and a respiratory etiology is most common in children. Fever after pediatric cardiac arrest is common and is associated with poor outcomes [8]. Therefore, TTM for pediatric cardiac arrest should be divided into two clinical scenarios: shockable rhythm (VT/VF) and non-shockable rhythm (non-VT/VT).

**Shockable rhythm (VT/VF)**

The 2015 American Heart Association (AHA) guidelines recommend TTM for adult cardiac arrest with an initial shockable rhythm (VT/VF) at a constant temperature between 32 °C and 36 °C for at least 24 h [3]. Based on this experience of cardiac arrest due to shockable rhythm in adults, TTM in children with shockable rhythm cardiac arrest should be the same as in adults.

**Non-shockable rhythm (non-VT/VT)**

Asphyxia is the most common cause of pediatric non-shockable rhythm cardiac arrest, and the etiologies of asphyxial cardiac arrest vary by age group. The 2015 AHA recommendations for TTM in pediatric cardiac arrest state, “For infants and children remaining comatose after out-of-hospital cardiac arrest (OHCA), it is reasonable either to maintain 5 days of continuous normothermia (36 °C–37.5 °C) or to maintain 2 days of initial continuous hypothermia (32 °C–34 °C) followed by 3 days of continuous normothermia. For infants and children remaining comatose after in-hospital cardiac arrest (IHCA), there is insufficient evidence to recommend cooling over normothermia [4]”.

Although the optimum duration at the target temperature (33 °C) in pediatric asphyxial cardiac arrest remains to be elucidated [9–12], experience of neonates with perinatal asphyxia suggests that comatose survivors who are resuscitated from asphyxial arrest may benefit from cooling at 33 °C for 72 h. In our recent study, 72 h of therapeutic hypothermia was associated with a better 1-month survival rate and 6-month neurological outcomes than normothermia in our pediatric patients with asphyxial out-of-hospital cardiac arrest. Further studies are required to address the duration of TTM in pediatric cardiac arrest [13].

**Hypoxic-ischemic encephalopathy in newborns**

**Fulfilling the TTM criteria of the AHA guidelines**

Therapeutic hypothermia is effective in term infants with hypoxic-ischemic encephalopathy. The 2015 AHA guidelines recommend that infants born at ≥36 weeks of gestation with evolving moderate to severe hypoxic-ischemic encephalopathy should be given TTM (32 °C–34 °C) within 6 h following birth, with continuation for 72 h and slow rewarming over at least 4 h [5].

**Not fulfilling the TTM criteria of the AHA guidelines**

However, it is unknown whether other neonatal patient groups may benefit from therapeutic hypothermia. Smit et al. conducted an observational study with prospective data of infants who did not fulfill the standard cooling criteria over a 6-year period in a regional cooling center [14]. They included infants cooled for >6 postnatal hours, late preterm infants, and infants with postnatal collapse, major cranial hemorrhage, congenital cardiac disease and surgical conditions, and found no significant differences in complication rates and long-term outcomes between the groups. They concluded that TTM can be considered for infants with neonatal encephalopathy who both do and do not fulfill the standard TTM criteria of the AHA guidelines.

**Traumatic brain injury**

Traumatic brain injury (TBI) is the other leading cause of morbidity and mortality in children. Fever after TBI exacerbates brain injury and worsens the outcome, and experimental models of TBI suggest that TTM is neuroprotective. TTM (32 °C–34.5 °C) has been trialed in pediatric patients both as a treatment for refractory intracranial hypertension and to improve neurological outcomes in the setting of severe (Glasgow Coma Scale score ≤8) TBI [15–19]. TTM for pediatric TBI has been demonstrated to improve refractory intracranial hypertension, but with no difference in neurologic outcomes and a trend toward higher mortality (Table 1).

Pediatric guidelines for severe TBI make distinct recommendations for the use of TTM to treat refractory hypertension and to improve neurological outcomes [1]. The guidelines provide level II evidence for recommending TTM (32 °C–33 °C) to treat refractory intracranial hypertension for a duration of up to 48 h, followed by rewarming relatively slowly to prevent rebound intracranial hypertension (0.5–1 °C) over 12–24 h. Therefore, TTM (32 °C–34 °C for
Table 1: Clinical trials of targeted temperature management on severe pediatric traumatic brain injury.

| References            | Case no. | Age (y) | Goal temp (°C) | Duration of TTM (h) | Outcome                                                                 |
|-----------------------|----------|---------|----------------|---------------------|-------------------------------------------------------------------------|
| Biswas et al. (PCS) (2002) [15] | 21       | 1–11    | 32–34          | 48                  | TH decreased ICP                                                       |
|                       |          |         |                |                     | No difference of outcome                                               |
|                       |          |         |                |                     | (3 m PCPC: HT 50% versus NT 63.7%)                                     |
| Adelson et al. (phase II RCT) (2005) [16] | 75       | 6.8 ± 3.4 | 32–33          | 48                  | TH decreased ICP, rebound ICP in some patients                         |
| Hutchison et al. (multinational RCT) (2008) [17] | 225      | 9.8 ± 4.9 | 32.5           | 24                  |                                                                          |
| Adelson et al. (phase III RCT) (2013) [18] | 77       | 3.4–14.6 | 32–33          | 48–72               | No difference of outcome                                               |
| Beca et al. (phase II RCT) (2015) [19] | 92       | 6.9–14.2 | 32–33          | 72                  | No difference of outcome                                               |
|                       |          |         |                |                     | (12 m PCPC: HT 83% versus NT 88%)                                      |

Abbreviations: Temp: temperature; TTM: targeted temperature management; TH: therapeutic hypothermia; ICP: intracranial pressure; m: months; RCT: randomized controlled trial; PCPC: Pediatric Cerebral Performance Category; GOS: Glasgow outcome scale; [#]: reference.

48–72 h) to treat refractory intracranial hypertension in children with TBI should be effective, although the rewarming phase is critical and should be conducted at a very slow rate (0.5–1 °C over 12–24 h).

Refractory status epilepticus

Refractory status epilepticus is associated with high morbidity and mortality. In animal models, hypothermia has been shown to abort seizures [20]. The antiepileptic effect of hypothermia remains unclear, however hypotheses include reduction of presynaptic excitatory transmitter release, alterations of postsynaptic voltage-gated channels, and disturbance of membrane polarity via ion pumps [21]. Although no prospective comparative data exist regarding the use of controlled normothermia or therapeutic hypothermia in pediatric refractory status epilepticus, many case reports have demonstrated the effectiveness of therapeutic hypothermia in treating refractory status epilepticus in children [22–27]. Interesting, Shein et al. reported a 4-month-old child developed SE that was refractory to multiple antiepileptic drug treatment, including continuous midazolam infusion. Finally, electrographic seizures stopped after a 43-h period of therapeutic hypothermia with a target rectal temperature of 33–34 °C. However, seizures recurred 10 h after rewarming. The ketogenic diet was started and seizures were controlled within 48 h of institution of the ketogenic diet [25]. Because both of therapeutic hypothermia and a ketogenic diet have multiple neuroprotective mechanism, it is reasonable that concurrent therapeutic hypothermia and a ketogenic diet may be considered for treating refractory status epilepticus in children [28]. Because of various etiologies and no standard protocol in these case reports, it is difficult to summarize the best temperature and duration of TTM in pediatric refractory status epilepticus. Table 2 summarizes the published literature for targeted temperature management in pediatric refractory status epilepticus.

The Neurocritical Care Society (NCS) guidelines for the treatment of status epilepticus in adults report that therapeutic hypothermia is an emerging therapy with limited data on the safety and effectiveness for refractory status epilepticus. Therefore, they recommend only using this therapy for patients with refractory status epilepticus who do not respond to conventional antiepileptic drug treatment [29,30]. A recent review by the Pediatric Status Epilepticus Research Group also reported that therapeutic hypothermia is an emerging therapy for refractory status epilepticus, but made no treatment recommendations [29,31].

Acute encephalitis/encephalopathy

Acute encephalopathy/encephalopathy encompasses infectious encephalitis, post-infectious encephalitis, and bacterial meningitis, and is also one of the most important causes of mortality and severe neurological sequelae in infants and children. The rationale for using therapeutic hypothermia in acute encephalitis/encephalopathy is to mitigate cytokine-mediated inflammation that may be exacerbated by fever and sepsis [32]. However, only two retrospective studies and a few case reports have reported the use of TTM to treat acute encephalitis/encephalopathy due to various viral and post-viral pathologies [29,32–36] (Table 3). Kawano et al. reported 27 children with acute encephalopathy/encephalitis receiving hypothermia (33–35 °C) compared with 16 children receiving normothermia. They found early hypothermia (≤12 h) could improve neurologic outcomes (Pediatric Cerebral Performance Category Scale ≥ grade 3 (early hypothermia (≤12 h) 14/17 (82.4%) versus late hypothermia (>12 h) 2/10 (20%) versus normothermia 9/16 (56.3%)) [35]. Nishiyama et al. retrospectively evaluated 57 children with acute encephalopathy and
AST levels below 90 IU/l, including 23 children received TTM (34.5–36 °C) and they concluded that TTM associated with better neurologic outcome Pediatric Cerebral Performance Category Scale with grade 1 in acute encephalopathy without AST elevation (TTM 23/23 (100%) versus normothermia 24/34 (70.6%)) [36]. The results of these studies showed that TTM was effectiveness in improving the neurological outcomes of acute encephalitis/encephalopathy; however there are currently no reports of the use of TTM for pediatric bacterial meningitis.

Although there are comprehensive guidelines for the diagnosis and treatment of pediatric encephalitis and meningitis [29,37–39], TTM is only briefly mentioned as an adjunctive therapy for bacterial meningitis [37]. Apart from this, high-quality studies with a large number of cases investigating the effectiveness and safety of the clinical methods used in TTM for acute encephalitis/encephalopathy are lacking.

### Post-anoxic encephalopathy (near drowning, carbon monoxide intoxication)

There is currently no consensus on the optimal therapy for post-anoxic encephalopathy without cardiac arrest secondary to near drowning or carbon monoxide (CO) poisoning.
Hepatic encephalopathy

Hepatic encephalopathy is often complicated by increased intracranial pressure (ICP), and hypothermia can reduce ICP by modulating multiple pathophysiologic mechanisms that are believed to be important in its pathogenesis. The potential of using TTM to lower ICP in patients with hepatic encephalopathy has been explored in adults. The results of three adult case series showed that TTM (32 °C–33 °C) was an effective and safe bridge to liver transplants in patients with acute hepatic failure with increased ICP resistant to standard medical therapy [46–48]. However, no pediatric case series have been reported (Table 4). Further studies are needed to confirm the effect of TTM on pediatric hepatic encephalopathy.

Summary

Acute encephalopathy in children and newborns involves various pathological conditions such as cardiac arrest, asphyxia, infection, post-anoxic and metabolic issues caused by brain dysfunction. Fever in the early period of acute

and CO-associated delayed neurological sequelae. Only a few case reports and small retrospective studies have reported on the use of TTM for post-anoxic encephalopathy secondary to near drowning or acute CO poisoning and CO-associated delayed neurological sequelae. Conn et al. reported remarkable recovery results with the use of hypothermia in near-drowning patients [40]. However, two small retrospective studies suggested that the application of deep and sustained hypothermia in near drowning patients with no vital signs on admission only increased the survival rate but did not improve neurological outcomes [41,42]. With regards to CO poisoning, Feldman et al. reported that a combination of hyperbaric oxygen and TTM produced successful results. In addition, the authors suggested that the use of bundle therapy with TTM-based methods may be considered [43]. Moreover, adult cardiac arrest and neonatal asphyxia studies have also shown that TTM can improve neurologically intact survival, suggesting that its efficacy in asphyxial injury should be reconsidered [44,45]. Based on experience with neonatal asphyxia, we suggest TTM (32 °C–34 °C) continuation for 72 h, and slow rewarming with 0.5–1 °C over 12–24 h. Further investigations are warranted regarding the effects of TTM on post-anoxic encephalopathy.

Table 4 Summary of published literature of targeted temperature management for hepatic encephalopathy.

| References            | Case no. | Age (y) | Goal temp (°C) | Duration of TTM (h) | IICP before and after hypothermia |
|-----------------------|----------|---------|----------------|--------------------|----------------------------------|
| Jalan et al. (PCS) (1999) [46] | 7        | 16–46   | 32–33          | 8–14               | 45 (25–49) mm Hg reduced to 16 (13–17) mm Hg |
| Jalan et al. (PCS) (2003) [47]  | 5        | 20–38   | 32–33          | —                  | No significant increase in ICP during the OLT |
| Jalan et al. (PCS) (2004) [48]  | 14       | 24 ± 3.1| 32–33          | 10–118             | 36.5 ± 2.7 mm Hg reduced to 16.8 ± 1.5 mm Hg |

Abbreviations: Temp: temperature; TTM: targeted temperature management; ICP: intracranial pressure; OLT: orthotopic liver transplantation; PCS: prospective cohort study; [#]: reference.

Table 5 The protocol of targeted temperature management in selected clinical scenarios at our hospital.

| Clinical Scenario                      | Protocol (Targeted temperature and duration) |
|----------------------------------------|---------------------------------------------|
| Cardiac arrest                         |                                             |
| Shockable rhythm CA (VT or VF)         | 32–34 °C or 36 °C at least 24 h             |
| Non-shockable rhythm CA (non-VT or VF) | 32–34 °C for 2 days following 3 day normothermia or 5 days of normothermia (36 °C–37.5 °C) |
| Neonatal hypoxic-ischemic encephalopathy (HIE) | Moderate or severe HIE, should be treated within 6 h of delivery to 32–34 °C for 72 h, at slow rewarming rate |
| Neonatal HIE (fulfilling the AHA guideline criteria)* |                                             |
| Neonatal HIE-other (not fulfilling the AHA guideline criteria) | 32–34 °C for 72 h, at slow rewarming rate |
| Others                                 |                                             |
| Traumatic brain injury with severe IICP | 32–34 °C for 48 h, at slow rewarming rate (0.5–1 °C over 12–24 h) |
| Status epilepticus                     |                                             |
| Acute encephalitis/encephalopathy      | Stage of SE based protocol:                |
|                                         | SE: 34–36 °C for 12–24 h,                |
|                                         | RSE: 33–35 °C for 1–2 days,              |
|                                         | SRSE: 32–34 °C for 3–5 days, at slow rewarming rate   |
|                                         | GCS based protocol:                      |
|                                         | GCS: 9–11: 34–36 °C for 48–72 h          |
|                                         | GCS: ≤8: 32–34 °C for 48–120 h          |
| Hypoxic encephalopathy (Near drowning, CO intoxication) | 32–34 °C for 72 h, at slow rewarming rate |
| Hepatic encephalopathy                 | 32–33 °C bridge to liver transplant       |

* The AHA guidelines criteria: Infants born at ≥ 36 weeks of gestation, evolving moderate to severe hypoxic-ischemic encephalopathy, within 6 h following birth.
encephalopathy in children and newborns are associated with worse outcomes. Close temperature monitoring and the use of TTM to prevent fever in the acute stage may therefore be a vital component of neurocritical care support. In children and newborns with acute encephalopathy, it is preferable to develop protocol-based treatment according to the clinical scenario and the severity of complications (Table 5). A prospective, protocol-based trial using different strategies of TTM for various clinical scenarios is needed.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration
Part of the content of this article was presented at the 1st Congress of Pediatric Neurocritical Care Consortium, 23 March, 2019, Taipei, Taiwan.

Conflicts of Interest
The authors declare no conflicts of interest.

Acknowledgments
The authors would like to thank all co-authors who provided their clinical experience and knowledge.

REFERENCES

[1] Kochanek PM, Carney N, Adelson PD, Ashwal S, Bell MJ, Bratton S, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents-second edition. Pediatr Crit Care Med 2012;13(Suppl 1):S1–S82.

[2] Kleinman ME, Chameides L, Schexnayder SM, Samson RA, Hazinski MF, Atkins DL, et al. Part 14: pediatric advanced life support: 2010 American heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2010;122:S876–908.

[3] Donnino MW, Andersen LW, Berg KM, Reynolds JC, Nolan JP, Morley PT, et al. ILCOR ALS Task Force. Temperature management after cardiac arrest: an advisory statement by the advanced life support task force of the international liaison committee on resuscitation and the American heart association emergency cardiovascular care committee and the council on cardiopulmonary, critical care, perioperative and resuscitation. Circulation 2015;132:2448–56.

[4] de Caen AR, Berg MD, Chameides L, Gooden CK, Hickey RW, Scott HF, et al. Part 12: pediatric Advanced Life Support: 2015 American heart association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2015;132(18 Suppl 2):S526–42.

[5] Wyckoff MH, Aziz K, Escobedo MB, Kapadia VS, Kattwinkel J, Perlman JM, et al. Part 13: neonatal Resuscitation: 2015 American heart association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2015;132(Suppl 2):S543–60.

[6] Benedetti GM, Silverstein FS. Targeted temperature management in pediatric neurocritical care. Pediatr Neurol 2018;88:12–24.

[7] Cariou A, Payen JF, Aselhounne K, Audibert G, Botte A, Brissaud O, et al. Targeted temperature management in the ICU: guidelines from a French expert panel. Ann Intensive Care 2017;7:70.

[8] Bembea MM, Nadkarni VM, Diener-West M, Venugopal V, Carey SM, Berg RA, et al. American Heart Association National Registry of Cardiopulmonary Resuscitation Investigators. Temperature patterns in the early post-resuscitation period after pediatric in hospital cardiac arrest. Pediatr Crit Care Med 2010;11:723–30.

[9] Doherty DR, Parshuram CS, Gaboury I, Hoskote A, Lacroix J, Tucci M, et al. Hypothermia therapy after pediatric cardiac arrest. Circulation 2009;119:1492–500.

[10] Fink EL, Clark RS, Kochanek PM, Bell MJ, Watson RS. A tertiary care center’s experience with therapeutic hypothermia after pediatric cardiac arrest. Pediatr Crit Care Med 2010;11:66–74.

[11] Moler FW, Silverstein FS, Holubkov R, Slomine BS, Christensen JR, Nadkarni VM, et al. Therapeutic hypothermia after in-hospital cardiac arrest in children. N Engl J Med 2017;376:318–29.

[12] Moler FW, Silverstein FS, Holubkov R, Slomine BS, Christensen JR, Nadkarni VM, et al. Therapeutic hypothermia after out-of-hospital cardiac arrest in children. N Engl J Med 2015;372:1898–908.

[13] Lin JJ, Lin CY, Hsia SH, Wang HS, Chiang MC, Lin KL, iCNS Group. 72-h therapeutic hypothermia improves neurological outcomes in paediatric asphyxial out-of-hospital cardiac arrest-An exploratory investigation. Resuscitation 2018;133:180–6.

[14] Smit E, Liu X, Jary S, Cowan F, Thoresen M. Cooling neonates who do not fulfil the standard cooling criteria - short- and long-term outcomes. Acta Paediatr 2015;104:138–45.

[15] Biswas AK, Bruce DA, Sklar FH, Bokovoy JL, Sommerauer JF. Treatment of acute traumatic brain injury in children with moderate hypothermia improves intracranial hypertension. Crit Care Med 2002;30:2742–51.

[16] Adelson PD, Ragheb J, Kanev P, Brockmeyer D, Beers SR, Brown SD, et al. Phase II clinical trial of moderate hypothermia after severe traumatic brain injury in children. Neurosurgery 2005;56:740–54.

[17] Hutchison JS, Ward RE, Lacroix J, Hébert PC, Barnes MA, Bohn DJ, et al. Hypothermia therapy after traumatic brain injury in children. N Engl J Med 2008;358:2447–56.

[18] Adelson PD, Wisniewski SR, Beca J, Brown SD, Bell M, Muizelaar JP, et al. Comparison of hypothermia and normothermia after severe traumatic brain injury in children (Cool Kids): a phase 3 randomised controlled trial. Lancet Neurol 2013;12:546–53.

[19] Beca J, McSharry B, Erickson S, Yung M, Schibler A, Slater A, et al. Hypothermia for traumatic brain injury in children: A phase II randomized controlled trial. Crit Care Med 2015;43:1458–66.

[20] Swinyard EA, Toman JE. Effects of alterations in body temperature on properties of convulsive seizures in rats. Am J Physiol 1948;154:207–10.

[21] Newmyer R, Mendelson J, Pang D, Fink EL. Targeted temperature management in pediatric central nervous system disease. Curr Treat Options Pediatr 2015;1:38–47.
[22] Vastola EF, Homan R, Rosen A. Inhibition of focal seizures by moderate hypothermia. A clinical and experimental study. Arch Neurol 1969;20:430–9.

[23] Orlowski JP, Erenberg G, Lueders H, Cruse RP. Hypothermia and barbiturate coma for refractory status epilepticus. Crit Care Med 1984;12:367–72.

[24] Elting JW, Naalt J, Fock JM. Mild hypothermia for refractory focal status epilepticus in an infant with hemimegalencephaly. Eur J Paediatr Neurol 2010;14:452–5.

[25] Shein SL, Reynolds TQ, Gedela S, Kochanek PM, Bell MJ. Therapeutic hypothermia for refractory status epilepticus in a child with malignant migrating partial seizures of infancy and SCN1A mutation: a case report. Ther Hypothermia Temp Manag 2012;2:144–9.

[26] Lin JJ, Lin KL, Hsia SH, Wang HS, Chou IJ, Lin YT, et al. Application of ketogenic diet for infection-related epilepsy syndrome in two patients. Pediatr Neurol 2012;47:448–50.

[27] Guilliams K, Rosen M, Buttram S, Zempel J, Pineda J, Miller B, et al. Hypothermia for pediatric refractory status epilepticus. Epilepsia 2013;54:1586–94.

[28] Lin KL, Lin JJ, Wang HS. Application of ketogenic diet for pediatric neurocritical care. Biomed J 2020;43:218–25.

[29] Lin JJ, Lin KL. The Pros and cons of therapeutic hypothermia for acute encephalitis and refractory status epilepticus. In: Hideo Y, Solomon L, Mand Akihisa O, editors. Acute encephalopathy and encephalitis in infancy and its related disorders. Elsevier Inc; 2018. p. 215–8.

[30] Brophy GM, Bell R, Claassen J, Aldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012;17:3–23.

[31] Sanchez Fernandez I, Abend NS, Agadi S, An S, Arya R, Carpenter J, et al. Gaps and opportunities in refractory status epilepticus research in children: a multi-center approach by the Pediatric Status Epilepticus Research Group (pSERG). Seizure 2014;23:87–97.

[32] Yokota S, Imagawa T, Miyamae T, Ito S, Nakajima S, Nezu A, et al. Hypothetical pathophysiology of acute encephalopathy and encephalitis related to influenza virus infection and hypothermia therapy. Pediatr Int 2000;42:197–203.

[33] Vargas WS, Merchant S, Solomon G. Favorable outcomes in acute necrotizing encephalopathy in a child treated with hypothermia. Pediatr Neurol 2012;46:387–9.

[34] Ichikawa K, Motoi H, Oyama Y, Watanabe Y, Takeshita S. Fulminant form of acute disseminated encephalomyelitis in a child treated with mild hypothermia. Pediatr Int 2013;55:e149–51.

[35] Kawano G, Iwata O, Iwata S, Kawano K, Obu K, Kuki I, et al. Determinants of outcomes following acute child encephalopathy and encephalitis: pivotal effect of early and delayed cooling. Arch Dis Child 2011;96:936–41.

[36] Nishiyama M, Tanaka T, Fujita K, Maruyama A, Nagase H. Targeted temperature management of acute encephalopathy without AST elevation. Brain Dev 2015;37:328–33.

[37] Chaudhuri A, Martinez-Martin P, Kennedy PG, Andrew Seaton R, Portegies P, Bojar M, et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. Eur J Neurol 2008;15:649–59.

[38] Kneen R, Michael BD, Mensor E, Mehta B, Easton A, Hemingway C, et al. Management of suspected viral encephalitis in children -association of British neurologists and British paediatric allergy, immunology and infection group national guidelines. J Infect 2012;64:449–77.

[39] Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267–84.

[40] Conn AW, Edmonds JF, Barker GA. Cerebral resuscitation in near-drowning. Pediatr Clin N Am 1979;6:691–701.

[41] Bohn DJ, Biggar WD, Smith CR, Conn AW, Barker GA. Influence of hypothermia, barbiturate therapy, and intracranial pressure monitoring on morbidity and mortality after near-drowning. Crit Care Med 1986;14:529–34.

[42] Biggart MJ, Bohn DJ. Effect of hypothermia and cardiac arrest on outcome of near-drowning accidents in children. J Pediatr 1990;117:79–83.

[43] Feldman J, Renda N, Markovitz GH, Chin W, Sprau SE. Treatment of carbon monoxide poisoning with hyperbaric oxygen and therapeutic hypothermia. Undersea Hyperb Med 2013;40:71–9.

[44] Hypothermia after cardiac arrest study group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002;346:549–56.

[45] Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;346:557–63.

[46] Jalan R, O Damink SW, Deutz NE, Lee A, Hayes PC. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure. Lancet 1999;354:1164–8.

[47] Jalan R, Olde Damink SW, Deutz NE, Hayes PC, Lee A. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology 2004;127:1338–46.

[48] Jalan R, Olde Damink SW, Deutz NE, Davies NA, Garden OJ, Madhavan KK, et al. Moderate hypothermia prevents cerebral hyperemia and increase in intracranial pressure in patients undergoing liver transplantation for acute liver failure. Transplantation 2003;75:2034–9.